Research Article

The Role of the Immune System in Nevirapine-Induced Subclinical Liver Injury of a Rat Model

Table 2

Average weights (mean ± SD) and liver function tests of rats ( 𝑛 = 5 ) in the chronic phase after 7, 14, and 21 days of dosing.

GroupWeight (g)Liver function tests (units/L)
(n = 5)Before RxAfter RxChangeALPALTAST

Untreated
 7 days392 ± 13404 ± 1212 ± 4262.5 ± 1167.8 ± 24169.3 ± 107
 14 days399 ± 14419 ± 2121 ± 10273.8 ± 5755.4 ± 5115.8 ± 10
 21 days376 ± 24397 ± 1122 ± 4285.0 ± 3457.8 ± 6120.8 ± 15
(S + NVP)
 7 days264 ± 5274 ± 1110 ± 7194.8 ± 3158.5 ± 10139.0 ± 58
 14 days260 ± 8278 ± 3217 ± 24208.7 ± 3175.3 ± 6126.0 ± 25
 21 days279 ± 14310 ± 431 ± 11152.0 ± 6449.0 ± 7112.3 ± 12
(LPS + NVP)
 7 days271 ± 5256 ± 13−11 ± 9403.3 ± 28147.0 ± 13427.0 ± 40
 14 days269 ± 7277 ± 88.0 ± 4150.6 ± 1152.0 ± 12111.8 ± 26
 21 days272 ± 9295 ± 1323 ± 9165.0 ± 1233.8 ± 789.8 ± 14

Key: Rx: treatment (Rx refers to test groups); S: saline; NVP: nevirapine; LPS: lipopolysaccharide; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase.